MAIA衰弱亚组分析:D-Rd方案治疗不适合移植初诊骨髓瘤的长期随访
MAIA研究事后按衰弱状态分层分析D-Rd与Rd的长期结局。中位随访64.5个月,非衰弱组D-Rd的OS获益维持(HR 0.53,95%CI 0.37-0.76,P=0.0004),衰弱组OS HR点估计有利于D-Rd(0.79,95%CI 0.58-1.06,P=0.1128)。各衰弱亚组中D-Rd均改善PFS并提高深度缓解率,支持其在不适合移植初诊骨髓瘤中的获益。
要点
- 非衰弱患者中D-Rd较Rd显著改善OS(HR 0.53,95%CI 0.37-0.76,P=0.0004)。
- 衰弱患者OS HR点估计为0.79(95%CI 0.58-1.06,P=0.1128),未达统计学显著。
- 各衰弱亚组中D-Rd均改善PFS及提高≥CR和MRD阴性率(10⁻⁵)。
核心结论
- 长期随访显示D-Rd在不适合移植初诊骨髓瘤中,无论衰弱状态如何均改善PFS和深度缓解率,非衰弱组OS获益显著。
研究设计与样本
- MAIA研究的事后衰弱亚组分析,采用年龄、Charlson合并症指数和基线ECOG评分回顾性评估衰弱状态。
- 患者分为fit、intermediate、non-frail(fit+intermediate)和frail四类。
- 中位随访64.5个月。
主要发现
- 非衰弱组:D-Rd vs Rd的OS HR 0.53(95%CI 0.37-0.76,P=0.0004),中位OS分别为NR和69.8个月。
- 衰弱组:D-Rd vs Rd的OS HR 0.79(95%CI 0.58-1.06,P=0.1128),中位OS分别为NR和50.4个月。
- 各衰弱亚组中D-Rd较Rd均改善PFS,并提高完全缓解及以上率和MRD阴性率(10⁻⁵)。
- D-Rd治疗持续时间在各亚组中均长于Rd。
临床怎么用
- 对于不适合移植的初诊骨髓瘤患者,D-Rd方案在各衰弱亚组中均显示PFS和深度缓解获益。
- 衰弱患者应用D-Rd时,OS获益趋势需结合个体情况评估。
局限性
- 衰弱状态为基于基线特征的回顾性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status. We retrospectively performed frailty assessments using age, Charlson Comorbidity Index, and baseline Eastern Cooperative Oncology Group performance status score; patients were classified as fit, intermediate, non-frail (fit + intermediate), or frail. After a 64.5-month median follow-up, OS benefit of D-Rd versus Rd was maintained in the non-frail subgroup (median, not reached [NR] vs 69.8 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37-0.76; P = 0.0004); the OS HR point estimate favored D-Rd versus Rd in the frail subgroup (NR vs 50.4 months; HR, 0.79; 95% CI, 0.58-1.06; P = 0.1128). Improved PFS and rates of complete response or better and minimal residual disease negativity (10-5) were observed with D-Rd versus Rd across frailty subgroups. Duration of therapy was consistently longer with D-Rd versus Rd, highlighting the improved disease control and long-term tolerability of daratumumab in frail patients. These long-term data, although limited by the retrospective assessment of frailty using baseline characteristics, continue to support the therapeutic benefit of D-Rd in terms of improved PFS and higher rates of deep responses in transplant-ineligible NDMM, regardless of frailty status.
引用
- Facon T, Cook G, Usmani SZ, et al. MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma. Leukemia. 2026. PMID: 42839070. doi:10.1038/s41375-026-03128-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。